New England Professional Planning Group Inc. Sells 1,202 Shares of Pfizer Inc. $PFE

New England Professional Planning Group Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.1% in the second quarter, HoldingsChannel reports. The fund owned 28,147 shares of the biopharmaceutical company’s stock after selling 1,202 shares during the period. Pfizer makes up approximately 0.3% of New England Professional Planning Group Inc.’s holdings, making the stock its 16th largest holding. New England Professional Planning Group Inc.’s holdings in Pfizer were worth $682,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Bessemer Group Inc. grew its stake in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK grew its stake in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after acquiring an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp bought a new position in shares of Pfizer during the 1st quarter valued at approximately $8,283,000. Westbourne Investments Inc. bought a new position in shares of Pfizer during the 1st quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its stake in shares of Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.41.

Pfizer Stock Down 3.4%

Shares of PFE opened at $26.45 on Tuesday. The stock has a market capitalization of $150.38 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business’s 50 day simple moving average is $24.72 and its 200-day simple moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.